



May 19, 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : Outcome of Board Meeting-May 19, 2026

Stock Code : BSE – 539787, NSE – HCG

Reference : Regulation 30, 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”)

Further to our intimation dated May 01, 2026, and pursuant to Regulation 30, 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company at its meeting held on May 19, 2026, has, *inter alia*, considered and approved the following agenda:

1. Audited Financial Results of the Company (Standalone and Consolidated), Cash Flow Statement, Statement of Assets and Liabilities together with the Audit Report thereon for the quarter and year ended March 31, 2026.

We hereby declare that the Statutory Auditors of the Company, M/s. B S R & Co. LLP, have issued an Audit Report with an unmodified opinion on Audited Financial Results (Standalone and Consolidated) of the Company for the year ended March 31, 2026.

2. The divestment by way of sale of HealthCare Global Enterprises Limited’s (“the Company”) entire equity shareholding in BACC Health Care Private Limited (“BACC”) to Inviga Healthcare Fund I and its nominee (“Buyer”), for a consideration of INR 37,64,44,788 (Indian Rupees Thirty Seven Crores Sixty Four Lakhs Forty Four Thousand Seven Hundred and Eighty Eight Only), on the terms agreed under a Share Purchase Agreement (“SPA”) to be entered into amongst the Company, BACC and the Buyer (the “Proposed Transaction”). BACC is not a material subsidiary of the Company and is engaged in the business of fertility and reproductive healthcare services, which is not a core business activity of the Company.

The Proposed Transaction is a related party transaction and has been approved by the Audit Committee and the Board of Directors of the Company.

HealthCare Global Enterprises Limited

Reg Off: HCG Towers #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bengaluru - 560 027

Corp Off: #3, G-Floor, Tower Block, Unity Buildings Complex, Mission Road, Bengaluru - 560 027, Karnataka, India

91 80 4660 7700 | Email-query@hcgel.com | Website - www.hcgoncology.com | CIN: L15200KA1998PLC023489

Ahmedabad | Bengaluru | Bhavnagar | Chennai | Cuttack | Hubballi | Indore | Jaipur | Kalaburagi | Kenya | Kolkata | Mumbai | Nagpur | Nashik | Ongole | Rajkot | Ranchi | Shimoga | Vadodara | Vijayawada | Vizag



3. Re-appointment of Mr. Rajiv Maliwal (DIN: 00869035) as a Non-Executive Independent Director of the Company for a second term of five (5) years with effect from May 25, 2026, on the recommendation of the Nomination and Remuneration Committee. The re-appointment is subject to the approval of shareholders of the Company and that he shall not be liable to retire by rotation. Detailed disclosure in this regard shall be made separately.
4. Appointment of Mr. Sanjeev Kumar, as Chief Financial Officer and Key Managerial Personnel of the Company, with effect from May 25, 2026. Detailed disclosure in this regard shall be made separately.
5. Appointment of Mr. Ravi Gothwal as AVP - Investor Relations, designated as Senior Management Personnel of the Company with effect from May 19, 2026. Detailed disclosure in this regard shall be made separately.
6. Re-appointment of Mr. Vijay S. Shanbhag, as Internal Auditor under Section 138 of the Companies Act, 2013, with effect from May 30, 2026, for a term of 1 year. Detailed disclosure in this regard shall be made separately.

Please find enclosed herewith the Audited Financial Results (Standalone and Consolidated), Cash Flow Statement, Statement of Assets and Liabilities together with the Audit Report thereon for the quarter and year ended March 31, 2026.

The financial results are also being made available on the website of the Company and can be accessed at: <https://www.hcgoncology.com/>.

The meeting of the Board of Directors commenced at 11.30 a.m. and concluded at 10.30 p.m.

Kindly take the intimation on record and acknowledge receipt of the same.

Thanking you,

For HealthCare Global Enterprises Limited

Sunu Manuel
Company Secretary & Compliance Officer

Encl: a/a.

Independent Auditor's Report

To the Board of Directors of HealthCare Global Enterprises Limited Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of HealthCare Global Enterprises Limited (hereinafter referred to as the "Company") for the year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and

Vy

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Independent Auditor's Report (*Continued*)

HealthCare Global Enterprises Limited

presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Vy

Independent Auditor's Report (Continued)
HealthCare Global Enterprises Limited

Other Matters

- a. The standalone annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248WW-100022



Vikash Gupta

Partner

Bangalore

19 May 2026

Membership No.: 064597

UDIN:26064597RYCBWK6060

HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

(Rs. in Lakhs except share data)

Sl. No	Particulars	Quarter ended 31 March 2026	Preceding quarter ended 31 December 2025	Corresponding quarter ended 31 March 2025	Year ended 31 March 2026	Previous year ended 31 March 2025
		(Refer note 1)	Unaudited	(Refer note 1)	Audited	Audited
1	Income					
	(a) Revenue from operations	34,847	34,056	32,280	135,937	127,652
	(b) Income from government grant	174	160	158	593	397
	(c) Other income (refer note 4)	1,492	299	946	2,967	3,461
	Total income	36,513	34,515	33,384	139,497	131,510
2	Expenses					
	(a) Purchases of medical and non-medical items	9,513	8,850	7,875	35,864	32,125
	(b) Changes in inventories	(308)	261	71	(548)	(360)
	(c) Employee benefits expense (refer note 8)	5,078	5,187	5,211	21,192	22,058
	(d) Finance costs	2,019	2,061	2,250	8,646	8,414
	(e) Depreciation and amortisation expense	3,130	3,009	2,905	11,980	11,139
	(f) Medical consultancy charges	6,675	6,677	6,365	26,343	24,920
	(g) Other expenses (refer note 5 and 7)	6,549	7,811	7,027	29,520	27,774
	Total expenses	32,656	33,856	31,704	132,997	126,070
3	Profit before exceptional items and tax (1-2)	3,857	659	1,680	6,500	5,440
4	Exceptional items (refer note 2)	(4,752)	(786)	-	(5,538)	(3,482)
5	Profit/(loss) before tax (3+4)	(895)	(127)	1,680	962	1,958
6	Tax expense					
	- Current tax (refer note 13)	(820)	452	824	404	2,066
	- Deferred tax	(228)	(461)	(159)	(900)	(461)
	Total tax expense	(1,048)	(9)	665	(496)	1,605
7	Profit/(loss) for the period / year (5-6)	153	(118)	1,015	1,458	353
8	Other comprehensive income / (loss)					
	Items that will not be reclassified subsequently to profit or loss					
	- Remeasurements of the defined benefit plans	(14)	40	40	11	39
	- Income tax effect on above	3	(10)	(9)	(3)	(9)
	Other comprehensive income/ (loss) for the period / year, net of tax	(11)	30	31	8	30
9	Total comprehensive income/(loss) for the period / year (7+8)	142	(88)	1,046	1,466	383
10	Paid-up equity share capital (Face value of Rs. 10 each)	14,930	14,101	13,942	14,930	13,942
11	Reserves, i.e., 'Other equity'				145,548	105,190
12	Earnings/(loss) per equity share (face value of Rs. 10 each)	Not annualised	Not annualised	Not annualised	Annualised	Annualised
	(a) Basic (Rs.) (refer note 14)	0.11	(0.08)	0.71	1.03	0.25
	(b) Diluted (Rs.) (refer note 14)	0.11	(0.08)	0.71	1.03	0.25
	See accompanying notes to the Standalone Financial Results					



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

STANDALONE BALANCE SHEET		(Rs in Lakhs)	
Particulars	As at 31 March 2026	As at 31 March 2025	
	Audited	Audited	
A ASSETS			
I Non-current assets			
(a) Property, plant and equipment	69,443	58,043	
(b) Capital work in progress	1,379	2,261	
(c) Right-of-use assets	33,078	35,459	
(d) Goodwill	9,014	9,014	
(e) Other intangible assets	688	1,288	
(f) Financial assets			
(i) Investments (refer note 2, 5 and 12)	70,370	69,575	
(ii) Loans	201	3,777	
(ii) Other financial assets	8,564	7,651	
(g) Deferred tax assets (net)	381	-	
(g) Other tax assets (net)	6,913	5,385	
(h) Other non-current assets	3,539	3,882	
Total non current assets	203,570	196,335	
II Current assets			
(a) Inventories	2,524	1,976	
(b) Financial assets			
(i) Trade receivables	26,215	26,198	
(ii) Cash and cash equivalents	47,411	15,803	
(iii) Bank balance other than cash and cash equivalents above	-	10,611	
(iv) Loans	156	165	
(v) Other financial assets	6,121	6,595	
(c) Other current assets	2,510	2,697	
	84,937	64,045	
Investments classified as held for sale (refer note 2 (i))	3,227	-	
Total current assets	88,164	64,045	
Total assets	291,734	260,380	
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital (refer notes 3 and 8)	14,930	13,942	
(b) Other equity (refer notes 3 and 8)	145,548	105,190	
Total equity	160,478	119,132	
II Liabilities			
1 Non-current liabilities			
(a) Financials liabilities			
(i) Borrowings	31,506	30,357	
(ii) Lease liabilities	40,848	42,369	
(iii) Other financial liabilities	904	1,053	
(b) Provisions	1,632	1,240	
(c) Deferred tax liabilities (net)	-	517	
(d) Other non-current liabilities	3,325	3,428	
Total non - current liabilities	78,215	78,964	
2 Current liabilities			
(a) Financials liabilities			
(i) Borrowings	25,199	34,772	
(ii) Lease liabilities	4,640	4,268	
(iii) Trade payables			
Total outstanding dues of micro enterprises and small enterprises	421	209	
Total outstanding dues of creditors other than micro enterprises and small enterprises	15,801	15,007	
(iv) Other financial liabilities	2,730	4,060	
(b) Other current liabilities	2,290	2,100	
(c) Provisions	1,711	1,604	
(d) Current tax liabilities (net)	249	264	
Total current liabilities	53,041	62,284	
Total equity and liabilities	291,734	260,380	

See accompanying notes to the Standalone Financial Results



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Standalone Cash Flow Statement	(Rs in Lakhs)	
	For the year ended 31 March 2026	For the year ended 31 March 2025
	Audited	Audited
Particulars		
Cash flows from operating activities		
Profit / (loss) before tax	962	1,958
Adjustments for:		
Finance costs	8,646	8,414
Gain on investment revalued at FVTPL	(6)	(16)
Net gain on termination of lease	(9)	-
Guarantee commission income	(107)	(123)
Loss on sale of undertaking (refer note 9)	-	162
Remeasurement of contingent consideration (refer note 4)	-	(278)
Fair value change of financial liability	(488)	281
Finance lease income	(398)	(411)
Gain on disposal of property, plant and equipment	(13)	-
Trade receivable written off	-	973
Loss allowance on trade receivables	1,355	346
Expenses on employee stock option scheme	122	588
ESOP Cash Settlement (refer note 8)	(5,808)	-
Interest income	(1,783)	(1,488)
Income from government grant	(593)	(397)
Depreciation and amortisation expense	11,980	11,139
Net foreign exchange (gain)	(21)	(14)
Provision for diminution in value of investments / loans (refer note 2)	4,752	3,482
Movements in working capital:		
Changes in trade receivables	(1,350)	(7,797)
Changes in inventories	(548)	(289)
Changes in loans, financial assets and other assets	574	(2,309)
Changes in security deposits	-	-
Changes in trade payables, financial liabilities and other liabilities	(783)	1,988
Changes in provisions	510	242
Cash generated from operations	16,994	16,451
Income taxes paid (net of refunds)	(975)	(1,856)
Net cash generated from operating activities (A)	16,019	14,595
Cash flows from investing activities		
Fixed deposits invested	(10,020)	(10,863)
Proceeds from maturity of fixed deposits	20,197	1,527
Acquisition of property, plant and equipment and others	(15,417)	(13,272)
Proceeds from disposal of property, plant and equipment	196	-
Interest received	2,032	830
Investment in subsidiaries	(15,224)	(21,742)
Return of variable capital contribution	6,456	-
Payment for acquisition of business (refer note 9)	-	(1,880)
Loan given to subsidiary	(200)	-
Proceeds from repayments of related party loans	3,776	200
Proceeds from sub-lease receivable	623	467
Proceeds from sale of undertaking	-	10,000
Net cash (used) in investing activities (B)	(7,581)	(34,733)
Cash flows from financing activities		
Proceeds from issue of equity shares (refer notes 3 and 8)	44,885	156
Share issue expenses (refer note 3)	(483)	-
Proceeds from long-term borrowings	9,149	9,914
Repayment of long-term borrowings	(7,360)	(4,173)
Repayment of principal portion of lease liability	(3,325)	(1,022)
Interest paid on lease liability	(4,424)	(4,370)
Interest and other borrowing cost paid	(4,821)	(4,660)
Net cash generated from / (used in) financing activities (C)	33,621	(4,155)
Net increase/(decrease) in cash and cash equivalents (A+B+C)	42,059	(24,293)
Cash and cash equivalents at the beginning of the year	(12,175)	12,118
Cash and cash equivalents at the end of the year	29,884	(12,175)
Break up of cash and cash equivalents at the end of the year		
	For the year ended 31 March 2026	For the year ended 31 March 2025
Cash and cash equivalents at the end of the year (before adjustment of bank overdraft)	47,411	15,803
Less: Bank overdrafts repayable on demand	(17,527)	(27,978)
Cash and cash equivalents at the end of the year	29,884	(12,175)



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Notes:

1 This statement of standalone financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company') for the quarter and year ended 31 March 2026 has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 19 May 2026. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The figures for the year ended 31 March 2026 have been audited by the statutory auditor of the Company. The report of the statutory auditor is unqualified. The figures for the quarters ended 31 March 2026 and 31 March 2025 are the balancing figures between audited figures in respect of the full financial year and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review by the statutory auditor of the Company.

2 **Exceptional items:**

(i) During the quarter and year ended 31 March 2026, the management committed to a plan to divest the Company's entire equity interest in BACC Healthcare Private Limited ("BACC"), a wholly owned subsidiary engaged in the management of infertility treatment hospitals. Pursuant to the investor outreach process, non-binding offers were received from potential investors. Accordingly, the Company's investment in BACC, which was previously carried at cost less provision for diminution in value of investment, has been reclassified as an "Investments classified as held for sale". Consequently, the investment has been measured at the lower of its carrying amount and fair value less costs to sell. Accordingly, an impairment loss of Rs. 3,752 lakhs has been recognised as an exceptional item for the quarter and year ended 31 March 2026 based on the fair value of the consideration receivable, net of related expenses.

Subsequent to the balance sheet date, based on the recommendation of the Audit Committee, the Board of Directors at its meeting held on 19 May 2026, approved the divestment by way of sale of the Company's entire equity interest in BACC to Inviga Healthcare Fund I and its nominee, a related party, for a consideration of Rs. 3,764 lakhs, subject to working capital adjustments and customary closing conditions. Of the agreed consideration, Rs. 2,823 lakhs will be payable upfront and the balance Rs. 941 lakhs will be payable within 18 months from the date of sale. This being a transaction with related party, the Audit Committee has accorded its approval to the transaction in terms of Section 177 of the Companies Act, 2013 and Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(ii) During the quarter and year ended 31 March 2026, the recoverable amount of the Company's investment in HCG Kolkata Cancer Care LLP (formerly HCG EKO Oncology LLP), a wholly-owned subsidiary, was estimated to be lower than its carrying value, resulting in an impairment of Rs. 3,000 lakhs. As at 31 March 2026, the Company carried total investment of Rs. 13,157 lakhs in HCG Kolkata Cancer Care LLP, against which the cumulative provision for impairment is Rs. 6,120 lakhs. During the same period, based on a sustained improvement in operating performance of HCG Manavata Oncology LLP, a subsidiary, the conditions that had led to an impairment in earlier years no longer exist and accordingly an impairment reversal of Rs. 2,000 lakhs has been recognised. As at 31 March 2026, the Company's aggregate investment in HCG Manavata Oncology LLP amounts to Rs. 5,715 lakhs.

During the previous year ended 31 March 2025, the recoverable amount of investments in HCG NCHRI Oncology LLP was estimated to be lower than its carrying value resulting into an impairment of Rs. 3,482 lakhs. As at 31 March 2025, the Company carried total investment of Rs 6,634 lakhs and the total provision for impairment against the aforementioned investment of Rs 5,505 lakhs.

(iii) On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published certain Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of legal advice obtained and the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this development, the Company has presented such incremental impact as "Exceptional Items" during the previous quarter ended 31 December 2025. The incremental impact consisting of gratuity of Rs 640 lakhs and compensated absences of Rs 146 lakhs primarily arises due to change in wage definition. The Company will continue to monitor the finalisation of Central / State Rules and clarifications from the Governments on the other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

³ During the quarter ended 31 March 2026, the Company completed a rights issue of 8,294,566 fully paid up equity shares of face value Rs.10/- each for cash at an issue price of Rs. 512/- per equity share (including a securities premium of Rs. 502/- per equity share). The rights issue was executed in accordance with the provisions of the Companies Act, 2013 and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, following approvals by the Board of Directors. The shares were allotted on 27 March 2026 to eligible shareholders in the ratio of 1 equity share for every 17 fully paid up equity shares held as on the record date of 2 March 2026. The fresh allotment of equity shares through the Rights Issue has resulted in an increase of paid up equity share capital by Rs. 829 lakhs and securities premium reserve by Rs. 41,639 lakhs. Share issue expenses amounting to Rs. 483 lakhs have been adjusted against the securities premium reserve as per the applicable Ind AS and regulations. As at 31 March 2026, the total issue proceeds remain unutilised and are held in the Company's current bank account, pending deployment for the objects specified in the Letter of Offer.

⁴ Pursuant to the Business Transfer Agreements ("BTA") with SRJ Health Care Private Limited and Amrish Oncology Services Private Limited, the Company had acquired their comprehensive cancer care centre and Radiation unit / centre in Indore on a slump sale basis on 3 October 2023. As per the terms of the BTA, the Company had paid upfront consideration aggregating to Rs. 4,500 lakhs. The BTA also provided for contingent consideration to be paid after 12 months from the date of acquisition amounting to a maximum of Rs. 1,600 lakhs subject to achievement of the specified financial performance targets of the business acquired. Based on the Purchase Price Allocation report, an amount of Rs. 4,169 lakhs and Rs. 263 lakhs were recorded as Goodwill and contingent consideration, respectively in respect of this acquisition.

During the previous year ended 31 March 2025, the management remeasured the fair value of contingent consideration payable as Nil. Consequently, the contingent consideration of Rs 278 lakhs (including interest accrued) was written back as Other income.

⁵ During the previous year ended 31 March 2025, pursuant to the Share Purchase Agreement (the "Agreement") dated 28 June 2024 with Vizag Hospital And Cancer Research Centre Private Limited (VHCRPL) and its shareholders, the Company had acquired 51% equity shares of VHCRPL on 01 October 2024 for a consideration of Rs. 20,632 lakhs and acquired control of VHCRPL from 02 October 2024. Further as per the terms of the Agreement the Company had committed to acquire an additional 34% of equity share capital of VHCRPL for a consideration of Rs.15,400 lakhs (approx.) which was payable within 18 months from the date of first closing (i.e. 01 October 2024). The consideration for the balance 15% of equity share capital will be determined as per the terms of the Agreement.

The Company incurred Rs. 259 lakhs towards legal and professional fees in respect of this business acquisition which was charged-off in the statement of profit and loss as Other expenses in the previous year ended 31 March 2025.

Subsequent to 31 March 2026, the Company completed the acquisition of 34% of equity share capital of VHCRPL on 13 April 2026 for an aggregate purchase consideration of Rs. 15,450 lakhs.

⁶ During the previous year ended 31 March 2025, the Company had entered into an Amended and Restated Shareholders' Agreement ("Restated SHA") on 14 February 2025 with Aastha Oncology Private Limited ("AOPL") and HCG Medi-Surge Hospitals Private Limited ("Subsidiary"). The Restated SHA superseded the shareholders' agreement dated 28 March 2012 entered into by and between the Company, AOPL and the Subsidiary. The Restated SHA recorded the revised terms and conditions governing the management and governance of the Subsidiary, and the inter se rights and obligations between the Company and AOPL in respect of the Subsidiary. The Restated SHA also revised the terms of exit and the underlying Put Option with AOPL.

Pursuant to this amendment, the Company has the option to settle put option granted to AOPL at its sole discretion either by payment of equivalent cash or through the grant of equity shares of the Company, at fair value.



7 During the previous year ended 31 March 2025, the Board of Directors of the Company had approved a share purchase agreement (SPA) dated 23 February 2025 between Aceso Company Pte. Ltd. ('Seller'), Hector Asia Holdings II Pte. Ltd. ('Purchaser 1') and KIA EBT II Scheme 1 ('Purchaser 2') (Purchaser 1 and Purchaser 2 collectively, 'Purchasers') and the Company, for the sale of upto 54% of the diluted voting share capital of the Company from Seller to the Purchasers. Hector Asia Holdings II Pte. Ltd. is an affiliate of funds, vehicles and/or entities managed and/or advised by Kohlberg Kravis Roberts & Co. L.P., which is an indirect subsidiary of KKR & Co. Inc.

Pursuant to the SPA, the Purchasers agreed to purchase from the Seller, the equity shares of the Company held by the Seller equivalent up to 54.00% of the diluted voting share capital of the Company. On 30 May 2025, the Purchasers acquired 51.59% of the diluted voting share capital of the Company at a price of INR 445 per share.

During the previous year ended 31 March 2025, the Company incurred Rs. 157 lakhs towards legal and professional fees in respect of this transaction which was charged-off in the statement of profit and loss as Other expenses during the quarter ended 30 June 2025.

Pursuant to the aforesaid transaction, the Seller was reclassified from the 'Promoter' category to the 'Public' category of the Company, and Purchaser 1 and Purchaser 2 were classified as 'Promoter' and 'Promoter Group', respectively, in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

8 During the previous year ended 31 March 2025, Board of Directors of the Company had approved an amendment to the ESOP 2021 Scheme at their meeting held on 21 February 2025 and the same was approved by the shareholders of the Company through a postal ballot on 27 April 2025. This provided an option to option holders ("Relevant Option Holder") to surrender up to maximum of 1,619,741 employee stock options ("Relevant ESOPs") held by them that vested prior to or immediately following the Trade Sale (as defined in the grant letter) and to provide them cash for such amount which was the lower of (i) the per share price at which a shareholder had a right to tender shares in any mandatory public offer prevailing at the time less exercise price of the Option, and (ii) per share value of INR 495/- less the exercise price of the option in accordance with the terms of the ESOP letters / agreement to be entered into between the Company and the Relevant Option Holder.

During the year ended 31 March 2026, the Company accepted a surrender of 1,619,741 options. The total value of cash consideration paid by the Company amounted to Rs 5,808 lakhs at the settlement price of Rs 495/- per option less the exercise price of the option. The amount paid in excess of the grant date fair value of the surrendered options, net of its tax impact was adjusted in the 'Retained Earnings' of the Company. Further, on account of the accelerated vesting of the remaining options granted under the ESOP 2021 scheme (which were not eligible for cash settlement), an amount of Rs. 69 lakhs was recognised by the Company under 'Employee benefit expenses' during the year ended 31 March 2026.

During the year ended 31 March 2026, 1,592,267 equity shares (year ended 31 March 2025: 125,683 equity shares) have been allotted pursuant to the exercise of equity share options. There were no exercise of equity share options during the quarter ended 31 March 2026.

9 During the previous year ended 31 March 2025, the Board of Directors, in their meeting held on 9 November 2024, had approved the following arrangements between the Company and HCG NCHRI Oncology LLP (a wholly owned subsidiary of the Company), effective 1 December 2024:

- i) Transfer of the Diagnostic business by the brand name of Triesta and the PET-CT & Cyclotron business located at Chennai from the Company to HCG NCHRI Oncology LLP by way of a slump sale; and
- ii) Transfer of the oncology hospital business at Nagpur from HCG NCHRI Oncology LLP to the Company by way of a slump sale.

The impact of business transfer mentioned in the point 9 (ii) above, was accounted for as per Appendix C of Ind AS 103 – 'Business Combinations' as a common control transaction.

10 The Board of Directors of the Company at its meeting held on 5 February 2026, based on the recommendation of the Nomination and Remuneration Committee have inter-alia considered and approved the introduction and adoption of HCG Employee Stock Option Scheme - 2026 ("HCG ESOS 2026"). The maximum number of shares that can be issued under the HCG ESOS 2026 shall be 74,21,455. The introduction and adoption of the HCG ESOS 2026, shall be subject to the approval by the shareholders' of the Company and as per SEBI (Share Based Employee Benefits and Sweat Equity) Regulations 2021.



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489


Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

- ¹¹ During the previous year ended 31 March 2025, Aceso Company Pte. Ltd, the erstwhile Promoter of the Company, through its parent Aceso Investment Holdings Pte. Ltd. ("AIHPL") had proposed making bonus payments directly to certain key managerial personnel and employees of the Company ("Identified Employees") without the Company being party to such an arrangement subject to such conditions as AIHPL may determine at its sole discretion, as consideration to the Identified Employees for performing their duties towards enhancement of shareholder value. The transaction was duly approved by the Board of Directors of the Company in their meeting held on 21 February 2025 and by the shareholders of the Company through a postal ballot on 27 April 2025 pursuant to the provisions of Regulation 26(6) and other relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid bonus amounting to Rs 4,830 lakhs was paid by AIHPL on 30 May 2025 to the Identified Employees after deducting the applicable taxes. Since, the Company was not a party to this transaction, there was no accounting impact in respect of the payment of this bonus by AIHPL in the standalone financial results for the year ended 31 March 2026.
- ¹² The Board of Directors, at its meeting held on 12 November 2025, has approved an additional investment of up to Rs. 700 lakhs (or equivalent USD) in the equity shares of Cancer Care Kenya Limited, a step-down subsidiary of the Company. During the preceding quarter ended 31 December 2025, the Company made an investment of Rs. 695 lakhs based on the fair value of the shares as determined by an independent valuer and the shares were allotted during the current quarter ended 31 March 2026.
- ¹³ The income tax expenses for the quarter and year ended 31 March 2026, is net of Rs. 1,820 lakhs relating to reversal of income taxes with respect to earlier years.
- ¹⁴ Earnings per share for the comparative periods/ year have been retrospectively adjusted for the bonus element in respect of Rights issue.
- ¹⁵ The Company has a single operating segment viz 'setting up and managing hospitals and medical diagnostic services'.

For and on behalf of the Board of Directors



Dr. Manish Mattoo

Bangalore, 19 May 2026

Executive Director, Chief Executive Officer and Chief Financial Officer



Independent Auditor's Report

To the Board of Directors of HealthCare Global Enterprises Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of HealthCare Global Enterprises Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), and its joint venture for the year ended 31 March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate/ consolidated audited financial statements/financial information of the subsidiaries and a joint venture, the aforesaid consolidated annual financial results:

- a. include the annual financial results of the entities mentioned in Annexure I to this audit report;
- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2026

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group and its joint venture in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us along with the consideration of reports of the other auditors referred to in sub paragraph no. (b) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Management's and Board of Directors'/Designated Partners' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group including its joint venture in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder

Registered Office:

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Independent Auditor's Report (Continued)

HealthCare Global Enterprises Limited

and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies/Designated Partners of limited liability partnerships (LLP) included in the Group and the respective Management and Board of Directors of its joint venture are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company/ LLP and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies/Designated Partners of LLP included in the Group and the respective Management and Board of Directors of its joint venture are responsible for assessing the ability of each company/ LLP to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors/designated partners either intends to liquidate the company/ LLP or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies/ Designated Partners of the LLP included in the Group and the respective Board of Directors of its joint venture is responsible for overseeing the financial reporting process of each company/ LLP.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on

VY.

Independent Auditor's Report (Continued)

HealthCare Global Enterprises Limited

the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group and its joint venture to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements/financial information of the entities within the Group and its joint venture to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial statements/financial information of such entities included in the consolidated annual financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph no. (b) of the "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matters

- a. The consolidated annual financial results include the results for the quarter ended 31 March 2026 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.
- b. The consolidated annual financial results include the audited financial results of 11 subsidiaries and 7 step down subsidiaries, whose financial statements/ financial informations reflect total assets (before consolidation adjustments) of Rs. 87,479 Lakhs as at 31 March 2026, total revenue (before consolidation adjustments) of Rs. 54,641 Lakhs and total net profit after tax (before consolidation adjustments) of Rs. 2,109 Lakhs and net cash inflows (before consolidation adjustments) of Rs 275 Lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditors. The consolidated annual financial results also include the Group's share of total net profit after tax of Rs. 146 Lakhs for the year ended 31 March 2026, as considered in the consolidated annual financial results, in respect of a joint venture, whose financial statements/financial informations have been audited by their respective independent auditors. The independent auditor's report on financial statements/ financial information of these entities have been furnished to us by the management.

Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters

Vy.

B S R & Co. LLP

Independent Auditor's Report (Continued)
HealthCare Global Enterprises Limited

with respect to our reliance on the work done and the reports of the other auditors.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Vikash Gupta

Partner

Bangalore

19 May 2026

Membership No.: 064597

UDIN:26064597VTZWOL5256

Independent Auditor's Report (Continued)
HealthCare Global Enterprises Limited

Annexure I

List of entities included in consolidated annual financial results.

Sr. No	Name of component	Relationship	Country of incorporation
1	BACC Healthcare Private Limited	Subsidiary	India
2	HCG Medi-Surge Hospitals Private Limited	Subsidiary	India
3	HCG Oncology LLP	Subsidiary	India
4	HCG Oncology Hospitals LLP (formerly known as Apex HCG Oncology Hospitals LLP)	Subsidiary	India
5	HCG Manavata Oncology LLP	Subsidiary	India
6	Malnad Hospital & Institute of Oncology Private Limited	Subsidiary	India
7	HealthCare Diwan Chand Imaging LLP	Subsidiary	India
8	HCG NCHRI Oncology LLP	Subsidiary	India
9	Nagpur Cancer Hospital & Research Institute Private Limited	Subsidiary	India
10	HCG Kolkata Cancer Care LLP (formerly known as HCG EKO Oncology LLP)	Subsidiary	India
11	HCG Rajkot Hospitals LLP (formerly known as HCG Sun Hospitals LLP)	Subsidiary	India
12	Niruja Product Development & Healthcare Research Private Limited	Subsidiary	India
13	HealthCare Global Senthil Multi Specialty Private Limited	Subsidiary	India
14	Suchirayu Health Care Solutions Limited	Subsidiary	India
15	HCG (Mauritius) Pvt. Ltd.	Subsidiary	Mauritius
16	Vizag Hospital and Cancer Research Centre Private Limited**	Subsidiary	India
17	HealthCare Global (Africa) Private Limited	Step-down subsidiary	Mauritius
18	Healthcare Global (Uganda) Private Limited	Step-down subsidiary	Uganda
19	Healthcare Global (Tanzania) Private Limited#	Step-down subsidiary	Tanzania
20	Healthcare Global (Kenya) Private Limited	Step-down subsidiary	Kenya

V4

Independent Auditor's Report (Continued)
HealthCare Global Enterprises Limited

Sr. No	Name of component	Relationship	Country of incorporation
21	Cancer Care Kenya Limited	Step-down subsidiary	Kenya
22	Vizag Hospital & Cancer Research Centre (Jharsuguda) Private Limited**	Step-down subsidiary	India
23	Vizag Hospital & Cancer Research Centre (Odisha) Private Limited**	Step-down subsidiary	India
24	Advanced Molecular Imaging Limited	Joint Venture	Kenya
**Acquired with effect from 02 October 2024 # wound up with effect from 02 March 2026			

Vy.

HealthCare Global Enterprises Limited
CIN : LI5200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India
Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

(Rs. in Lakhs except share data)

Sl. No.	Particulars	Quarter ended	Preceding quarter ended	Corresponding quarter ended	Year ended	Previous year ended
		31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
		(Refer note 1)	Unaudited	(Refer note 1)	Audited	Audited
1	Income					
	(a) Revenue from operations	65,029	63,118	58,343	253,843	221,814
	(b) Income from government grant	204	189	173	698	471
	(c) Other income (refer notes 4 and 5 (b))	1,267	247	1,022	2,422	2,481
	Total income	66,540	63,554	59,539	257,040	225,766
2	Expenses					
	(a) Purchases of medical and non-medical items	18,070	17,343	15,408	70,168	59,022
	(b) Changes in inventories	(399)	314	(5)	(938)	(962)
	(c) Employee benefits expense (refer note 10)	9,247	9,418	9,281	37,860	35,348
	(d) Finance costs	4,270	4,478	4,417	17,657	15,456
	(e) Depreciation and amortisation expense	6,281	6,065	5,807	24,417	21,134
	(f) Medical consultancy charges	14,033	13,912	12,920	54,907	48,167
	(g) Other expenses (refer notes 5 and 9)	11,774	11,359	10,340	45,965	41,982
	Total expenses	63,276	62,889	58,168	250,036	220,147
3	Profit before share of profit/(loss) of joint venture, exceptional items and tax (1-2)	3,264	665	1,371	7,004	5,619
4	Share of profit / (loss) of joint venture	52	(5)	(9)	146	77
5	Profit before exceptional items and tax (3+4)	3,316	660	1,362	7,150	5,696
6	Exceptional item (refer note 2)	(3,191)	(1,267)	-	(4,458)	-
7	Profit / (loss) before tax (5+6)	125	(607)	1,362	2,692	5,696
8	Tax expense					
	- Current tax (refer note 6)	(161)	441	1,256	1,976	2,866
	- Deferred tax (refer notes 6 and 7)	(118)	(258)	(571)	(1,562)	(2,053)
	Total tax expense/(credit)	(279)	183	685	414	813
9	Profit / (loss) for the period / year (7-8)	404	(790)	677	2,278	4,883
10	Other comprehensive income					
	(i) Items that will not be reclassified subsequently to profit or loss					
	- Remeasurements of the defined benefit plans	12	74	48	97	41
	- Income tax effect on above	(1)	(18)	(29)	(24)	(29)
	(ii) Items that will be reclassified to profit or loss					
	- Exchange differences on translation of financial statements of foreign operations	154	152	2	382	168
	Other comprehensive income for the period / year, net of tax	165	208	21	455	180
11	Total comprehensive income / (loss) for the period / year (9+10)	569	(582)	698	2,733	5,063
	Profit / (loss) for the period / year attributable to:					
	Owners of the Company	217	(943)	736	1,376	4,441
	Non-controlling interests	187	153	(59)	902	442
	Other comprehensive income / (loss) for the period / year attributable to					
	Owners of the Company	209	151	19	455	161
	Non-controlling interests	(44)	57	2	-	19
	Total comprehensive income / (loss) for the period / year attributable to					
	Owners of the Company	426	(792)	755	1,831	4,602
	Non-controlling interests	143	210	(57)	902	461
12	Paid-up equity share capital (Face value of Rs. 10 each)	14,930	14,101	13,942	14,930	13,942
13	Reserves, i.e., 'Other equity'				118,267	78,303
14	Earnings / (loss) per equity share (face value of Rs. 10 each)	Not annualised	Not annualised	Not annualised	Annualised	Annualised
	(a) Basic (Rs.) (refer note 15)	0.15	(0.66)	0.52	0.97	3.17
	(b) Diluted (Rs.) (refer note 15)	0.15	(0.66)	0.52	0.96	3.12
	See accompanying notes to the Consolidated Financial Results					



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

CONSOLIDATED BALANCE SHEET		(Rs in Lakhs)	
Particulars	As at 31 March 2026	As at 31 March 2025	
	Audited	Audited	
A ASSETS			
I Non-current assets			
(a) Property, plant and equipment	139,279	126,892	
(b) Capital work in progress	1,856	2,476	
(c) Right-of-use assets	64,836	69,411	
(d) Goodwill (refer note 2)	38,759	42,995	
(e) Other intangible assets	3,287	4,891	
(f) Investment in equity accounted investee	682	431	
(g) Financial assets			
(i) Investments	707	700	
(ii) Other financial assets	8,239	7,047	
(h) Deferred tax assets (net)	3,992	2,499	
(i) Other tax assets (net)	10,742	8,554	
(j) Other non-current assets	6,354	4,048	
Total non-current assets	278,733	269,944	
II Current assets			
(a) Inventories	5,982	5,302	
(b) Financial assets			
(i) Trade receivables	42,070	40,090	
(ii) Cash and cash equivalents	53,605	23,587	
(iii) Bank balance other than cash and cash equivalents above	487	11,183	
(iv) Loans	336	270	
(v) Other financial assets	1,129	498	
(c) Other current assets	3,241	3,450	
	106,850	84,380	
Assets included in disposal group held for sale (refer note 2)	6,671	-	
Total current assets	113,521	84,380	
Total assets	392,254	354,324	
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital (refer notes 3 and 10)	14,930	13,942	
(b) Other equity (refer notes 3, 8 and 10)	118,267	78,303	
Equity attributable to equity holders of the Company	133,197	92,245	
Non-controlling interests	7,824	6,760	
Total equity	141,021	99,005	
II Liabilities			
1 Non-current liabilities			
(a) Financials Liabilities			
(i) Borrowings	59,919	60,458	
(ii) Lease liabilities	75,998	77,509	
(iii) Other financial liabilities	6,995	6,340	
(b) Provisions	2,526	2,143	
(c) Deferred tax liabilities (net)	234	354	
(d) Other non-current liabilities	3,845	3,873	
Total non-current liabilities	149,517	150,677	
2 Current liabilities			
(a) Financials liabilities			
(i) Borrowings	31,122	39,765	
(ii) Lease liabilities	6,497	5,990	
(iii) Trade payables			
Total outstanding dues of micro enterprises and small	559	414	
Total outstanding dues of creditors other than micro	34,545	33,012	
(iv) Other financial liabilities	18,967	19,592	
(b) Other current liabilities	3,884	3,670	
(c) Provisions	2,338	1,935	
(d) Current tax liabilities (net)	360	264	
	98,272	104,642	
Liabilities included in disposal group held for sale (refer note 2)	3,444	-	
Total current liabilities	101,716	104,642	
Total equity and liabilities	392,254	354,324	
See accompanying notes to the Consolidated Financial Results			



HealthCare Global Enterprises Limited
CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Consolidated Cash Flow Statement		(Rs in Lakhs)	
Particulars	For the Year ended	For the Year ended	
	31 March 2026	31 March 2025	
	Audited	Audited	
Cash flows from operating activities			
Profit before tax	2,692	5,696	
Adjustments for:			
Finance costs	17,657	15,456	
Gain on investment revalued at FVTPL	(6)	(16)	
(Gain) / Loss on disposal of property, plant and equipment	(25)	106	
Trade receivable written off	-	973	
Loss allowance on trade receivables	2,185	1,067	
Expenses on employee stock option scheme	144	654	
ESOP Cash Settlement (refer note 10)	(5,808)	-	
Interest income	(1,433)	(1,588)	
Net gain on termination of lease	(9)	(102)	
Remeasurement of contingent consideration (refer note 4)	-	(278)	
Depreciation and amortisation expense	24,417	21,134	
Income from government grant	(698)	(471)	
Net foreign exchange (gain)	(15)	(8)	
Share of (profit) / loss of equity accounted investee	(146)	(78)	
Impairment of goodwill (refer note 2)	3,191	-	
Movements in working capital:			
Changes in trade receivables	(4,251)	(9,072)	
Changes in inventories	(938)	(961)	
Changes in loans, financial assets and other assets	(128)	(1,018)	
Changes in trade payables, financial liabilities and other liabilities	211	2,951	
Changes in provisions	852	454	
Cash generated from operations	37,892	34,899	
Income taxes paid (net of refunds)	(3,182)	(3,188)	
Net cash generated from operating activities (A)	34,710	31,711	
Cash flows from investing activities			
Fixed deposits invested	(11,062)	(11,790)	
Proceeds from maturity of fixed deposits	20,972	2,522	
Acquisition of property, plant and equipment and others	(29,210)	(20,887)	
Proceeds from disposal of property, plant and equipment	361	154	
Interest received	1,192	945	
Payment for asset acquisition (net of cash and cash equivalents)	-	(19,719)	
Net cash (used) in investing activities (B)	(17,747)	(48,775)	
Cash flows from financing activities			
Proceeds from issue of equity shares (refer notes 3 and 10)	44,885	156	
Share issue expenses (refer note 3)	(483)	-	
Amount received from minority stakeholder in the subsidiaries	59	-	
Proceeds from long-term borrowings	12,868	22,208	
Repayment of long-term borrowings	(11,902)	(7,756)	
Repayment of principle portion of lease liability	(4,662)	(2,616)	
Interest paid on lease liability	(8,429)	(8,200)	
Settlement of deferred consideration	-	(420)	
Interest and other borrowing cost paid	(8,269)	(7,616)	
Net cash generated / (used) in financing activities (C)	24,067	(4,244)	
Net increase/(decrease) in cash and cash equivalents (A+B+C)	41,030	(21,308)	
Cash and cash equivalents at the beginning of the year	(4,707)	16,601	
Cash and cash equivalents at the end of the year	36,323	(4,707)	

Break up of cash and cash equivalents at the end of the year	For the Year ended	For the Year ended
	31 March 2026	31 March 2025
Cash and cash equivalents at the end of the year as per Balance Sheet (before adjustment of bank overdraft)	53,605	23,587
Cash and cash equivalents classified as Assets included in disposal group held for sale (refer note 2)	551	-
Less: Bank overdrafts repayable on demand	(17,833)	(28,294)
Cash and cash equivalents at the end of the year	36,323	(4,707)



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

Notes to consolidated financial results:

1 This statement of consolidated financial results ('the Statement') of HealthCare Global Enterprises Limited ('the Company'), and its subsidiaries (collectively referred to as "the Group") and its joint venture for the quarter and year ended 31 March 2026 has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 19 May 2026. The Statement has been prepared in accordance with Indian Accounting Standards (Ind AS) as notified by the Ministry of Corporate Affairs pursuant to Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules 2015, as amended and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulations, 2015.

The consolidated figures for the year ended 31 March 2026 have been audited by the statutory auditor of the Company. The report of the statutory auditors is unqualified. The consolidated figures for the quarters ended 31 March 2026 and 31 March 2025 are the balancing figures, between audited figures in respect of the full financial year and the published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review by the statutory auditors of the Company.

2 Exceptional items:

(i) During the quarter and year ended 31 March 2026, the management committed to a plan to divest the Company's entire equity interest in BACC Healthcare Private Limited ("BACC"), a wholly owned subsidiary engaged in the management of infertility treatment hospitals. Pursuant to the investor outreach process, non-binding offers were received from potential investors. Accordingly, the assets and liabilities of BACC have been classified as a disposal group held for sale as at 31 March 2026. Along with the classification as held for sale, the carrying amount of goodwill allocated to the cash-generating unit (i.e., BACC) was assessed for impairment in accordance with Ind AS 36 and an impairment loss of Rs. 3,191 lakhs has been recognised as an exceptional item for the quarter and year ended 31 March 2026 based on the fair value of the consideration receivable, net of related expenses.

Subsequent to the balance sheet date, based on the recommendation of the Audit Committee, the Board of Directors at its meeting held on 19 May 2026, approved the divestment by way of sale of the Company's entire equity interest in BACC to Inviga Healthcare Fund I and its nominee, a related party, for a consideration of Rs. 3,764 lakhs, subject to working capital adjustments and customary closing conditions. Of the agreed consideration, Rs. 2,823 lakhs will be payable upfront and the balance Rs. 941 lakhs will be payable within 18 months from the date of sale. This being a transaction with related party, the Audit Committee has accorded its approval to the transaction in terms of Section 177 of the Companies Act, 2013 and Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(ii) On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published certain Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Group has assessed and disclosed the incremental impact of these changes on the basis of legal advice obtained and the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this development, the Group has presented such incremental impact as an "Exceptional Item" during the previous quarter ended 31 December 2025. The incremental impact consisting of gratuity of Rs. 1,043 lakhs and compensated absences of Rs 224 lakhs primarily arises due to change in wage definition. The Group will continue to monitor the finalisation of Central / State Rules and clarifications from the Governments on the other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

3 During the quarter ended 31 March 2026, the Company completed a rights issue of 8,294,566 fully paid up equity shares of face value Rs.10/- each for cash at an issue price of Rs. 512/- per equity share (including a securities premium of Rs. 502/- per equity share). The rights issue was executed in accordance with the provisions of the Companies Act, 2013 and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, following approvals by the Board of Directors. The shares were allotted on 27 March 2026 to eligible shareholders in the ratio of 1 equity share for every 17 fully paid up equity shares held as on the record date of 2 March 2026. The fresh allotment of equity shares through the Rights Issue has resulted in an increase of paid up equity share capital by Rs. 829 lakhs and securities premium reserve by Rs. 41,639 lakhs. Share issue expenses amounting to Rs. 483 lakhs have been adjusted against the securities premium reserve as per the applicable Ind AS and regulations. As at 31 March 2026, the total issue proceeds remain unutilised and are held in the Company's current bank account, pending deployment for the objects specified in the Letter of Offer.

4 Pursuant to the Business Transfer Agreements ("BTA") with SRJ Health Care Private Limited and Amrish Oncology Services Private Limited, the Company had acquired their comprehensive cancer care centre and Radiation unit / centre in Indore on a slump sale basis on 3 October 2023. As per the terms of the BTA, the Company had paid upfront consideration aggregating to Rs. 4,500 lakhs. The BTA also provided for contingent consideration to be paid after 12 months from the date of acquisition amounting to a maximum of Rs. 1,600 lakhs subject to achievement of the specified financial performance targets of the business acquired. Based on the Purchase Price Allocation report, an amount of Rs. 4,169 lakhs and Rs. 263 lakhs were recorded as Goodwill and contingent consideration, respectively in respect of this acquisition.

During the previous year ended 31 March 2025, the management remeasured the fair value of contingent consideration payable as Nil. Consequently, the contingent consideration of Rs 278 lakhs (including interest accrued) was written back as Other income.



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489

Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

- 5 a) During the previous year ended 31 March 2025, pursuant to the Share Purchase Agreement (the "Agreement") dated 28 June 2024 with Vizag Hospital And Cancer Research Centre Private Limited (VHCRPL) and its shareholders, the Company had acquired 51% equity shares of VHCRPL on 01 October 2024 for a consideration of Rs. 20,632 lakhs and acquired control of VHCRPL from 02 October 2024. Further as per the terms of the Agreement, the Company had committed to acquire an additional 34% of equity share capital of VHCRPL for a consideration of Rs.15,400 lakhs (approx.) which was payable within 18 months from the date of first closing (i.e. 01 October 2024). The consideration for the balance 15% of equity share capital will be determined as per the terms of the shareholder Agreement. Based on the purchase price allocation done by the management, an amount of Rs. 20,695 lakhs was recorded as Goodwill.
- The Company incurred Rs. 259 lakhs towards legal and professional fees in respect of this business acquisition which was charged-off in the statement of profit and loss as Other expenses in the previous year ended 31 March 2025.
- Subsequent to 31 March 2026, the Company completed the acquisition of 34% of equity share capital of VHCRPL on 13 April 2026 for an aggregate purchase consideration of Rs. 15,450 lakhs.
- b) During the quarter ended 31 March 2026, the Group has recognised a gain of Rs 700 lakhs relating to the trade receivables acquired through a business combination (acquisition of VHCRPL) on 02 October 2024 accounted as per Ind AS 103 'Business combination' on account of changes in the fair value (recoverability) of these receivables.
- 6 (a) The income tax expenses for the quarter and year ended 31 March 2026, is net of Rs 1,820 lakhs relating to reversal of income taxes with respect to earlier years.
- (b) During the year ended 31 March 2026, the management reassessed whether the Company's Subsidiary, HCG Oncology LLP would have sufficient taxable profits to utilize its unused tax losses in the foreseeable future considering the improvement in its performance and utilization of tax losses accumulated in the earlier years. Accordingly, based on the reasonable certainty of availability of future profits in the foreseeable future, the Group recognized a deferred tax asset/credit of Rs. 960 lakhs on the brought forward business losses and unabsorbed depreciation with respect to this subsidiary, during the year ended 31 March 2026.
- 7 During the previous year ended 31 March 2025, the Board of Directors, in their meeting held on 9 November 2024, had approved the following arrangements between the Company and HCG NCHRI Oncology LLP (a wholly owned subsidiary of the Company), effective 1 December 2024:
- 1) Transfer of the Diagnostic business by the brand name of Triesta and the PET-CT & Cyclotron business located at Chennai from the Company to HCG NCHRI Oncology LLP by way of a slump sale; and
- 2) Transfer of the Oncology Hospital business at Nagpur from HCG NCHRI Oncology LLP to the Company by way of a slump sale.
- The slump sale agreements have been accounted for as per the guidance contained in Indian Accounting Standards (IND AS) 103: Business Combination, in the standalone financial statements of the respective entities.
- Further, based on the management assessment of the reasonable certainty of availability of future profits in HCG NCHRI Oncology LLP, the Group had recognized a deferred tax asset/credit of Rs. 1,410 lakhs on the brought forward business losses and unabsorbed depreciation, during the previous year ended 31 March 2025
- 8 During the previous year ended 31 March 2025, the Company had entered into an Amended and Restated Shareholders' Agreement ('Restated SHA') on 14 February 2025 with Aastha Oncology Private Limited ('AOPL') and HCG Medi-Surge Hospitals Private Limited ('Subsidiary'). The Restated SHA superseded the shareholders' agreement dated 28 March 2012 entered into by and between the Company, AOPL and the Subsidiary. The Restated SHA recorded the revised terms and conditions governing the management and governance of the Subsidiary, and the inter se rights and obligations between the Company and AOPL in respect of the Subsidiary. The Restated SHA also revised the terms of exit and the underlying Put Option with AOPL.
- Pursuant to this amendment, the Company has the option to settle put option granted to AOPL at its sole discretion either by payment of equivalent cash or through the grant of equity shares of the Company, at fair value. Accordingly, the Company derecognised the put option liability amounting to Rs.10,600 lakhs and credited 'Other Equity' during the previous year ended 31 March 2025, as per the relevant Ind AS 32 "Financial Instruments: Presentation".
- 9 During the previous year ended 31 March 2025, the Board of Directors of the Company had approved a share purchase agreement (SPA) dated 23 February 2025 between Aceso Company Pte. Ltd. ('Seller'), Hector Asia Holdings II Pte. Ltd. ('Purchaser 1') and KIA EBT II Scheme 1 ('Purchaser 2') (Purchaser 1 and Purchaser 2 collectively, 'Purchasers') and the Company, for the sale of upto 54% of the diluted voting share capital of the Company from Seller to the Purchasers. Hector Asia Holdings II Pte. Ltd. is an affiliate of funds, vehicles and/or entities managed and/or advised by Kohlberg Kravis Roberts & Co. L.P., which is an indirect subsidiary of KKR & Co. Inc.
- Pursuant to the SPA, the Purchasers agreed to purchase from the Seller, the equity shares of the Company held by the Seller equivalent up to 54.00% of the diluted voting share capital of the Company. On 30 May 2025, the Purchasers acquired 51.59% of the diluted voting share capital of the Company at a price of INR 445/- per share.
- During the previous year ended 31 March 2025, the Company incurred Rs. 157 lakhs towards legal and professional fees in respect of this transaction which was charged-off in the statement of profit and loss as Other expenses during the quarter ended 30 June 2025.
- Pursuant to the aforesaid transaction, the Seller was reclassified from the 'Promoter' category to the 'Public' category of the Company, and Purchaser 1 and Purchaser 2 were classified as 'Promoter' and 'Promoter Group', respectively, in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.



HealthCare Global Enterprises Limited

CIN : L15200KA1998PLC023489


Regd. Office: HCG Tower, No. 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bengaluru 560 027, Karnataka, India

Corp. Office: Tower Block, Unity Building Complex, No. 3, Mission Road, Bengaluru 560 027, Karnataka, India

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 MARCH 2026

- 10 During the previous year ended 31 March 2025, Board of Directors of the Company had approved an amendment to the ESOP 2021 Scheme at their meeting held on 21 February 2025 and the same was approved by the shareholders of the Company through a postal ballot on 27 April 2025. This provided an option to option holders ("Relevant Option Holder") to surrender up to maximum of 1,619,741 employee stock options ("Relevant ESOPs") held by them that vested prior to or immediately following the Trade Sale (as defined in the grant letter) and to provide them cash for such amount which was the lower of (i) the per share price at which a shareholder had a right to tender shares in any mandatory public offer prevailing at the time less exercise price of the Option, and (ii) per share value of INR 495/- less the exercise price of the option in accordance with the terms of the ESOP letters / agreement to be entered into between the Company and the Relevant Option Holder.
- During the year ended 31 March 2026, the Company accepted a surrender of 1,619,741 options. The total value of cash consideration paid by the Company amounted to Rs 5,808 lakhs at the settlement price of Rs 495/- per option less the exercise price of the option. The amount paid in excess of the grant date fair value of the surrendered options, net of its tax impact was adjusted in the 'Retained Earnings' of the Company. Further, on account of the accelerated vesting of the remaining options granted under the ESOP 2021 scheme (which were not eligible for cash settlement), an amount of Rs. 69 lakhs was recognised by the Company under 'Employee benefit expenses' during the year ended 31 March 2026.
- During the year ended 31 March 2026, 1,592,267 equity shares (year ended 31 March 2025: 125,683 equity shares) have been allotted pursuant to the exercise of equity share options. There were no exercise of equity share options during the quarter ended 31 March 2026.
- 11 The Board of Directors of the Company at its meeting held on 5 February 2026, based on the recommendation of the Nomination and Remuneration Committee have inter-alia considered and approved the introduction and adoption of HCG Employee Stock Option Scheme - 2026 ("HCG ESOS 2026"). The maximum number of shares that can be issued under the HCG ESOS 2026 shall be 74,21,455. The introduction and adoption of the HCG ESOS 2026, shall be subject to the approval by the shareholders' of the Company and as per SEBI (Share Based Employee Benefits and Sweat Equity) Regulations 2021.
- 12 During the previous year ended 31 March 2025, Aceso Company Pte. Ltd, the erstwhile Promoter of the Company, through its parent Aceso Investment Holdings Pte. Ltd. ("AIHPL") had proposed making bonus payments directly to certain key managerial personnel and employees of the Company ("Identified Employees") without the Company being party to such an arrangement subject to such conditions as AIHPL may determine at its sole discretion, as consideration to the Identified Employees for performing their duties towards enhancement of shareholder value. The transaction was duly approved by the Board of Directors of the Company in their meeting held on 21 February 2025 and by the shareholders of the Company through a postal ballot on 27 April 2025 pursuant to the provisions of Regulation 26(6) and other relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid bonus amounting to Rs 4,830 lakhs was paid by AIHPL on 30 May 2025 to the Identified Employees after deducting the applicable taxes. Since, the Company was not a party to this transaction, there was no accounting impact in respect of the payment of this bonus by AIHPL in the consolidated financial results for the year ended 31 March 2026.
- 13 The Board of Directors, at its meeting held on 12 November 2025, approved an additional investment of up to Rs. 700 lakhs (or equivalent USD) in the equity shares of Cancer Care Kenya Limited, a step-down subsidiary of the Company. During the quarter ended 31 December 2025, the Company made an investment of Rs. 695 lakhs based on the fair value of the shares as determined by an independent valuer and the shares were allotted during the current quarter ended 31 March 2026.
- 14 During the quarter and year ended 31 March 2026, the Group completed the voluntary winding-up of Healthcare Global (Tanzania) Private Limited, a non-operating step-down subsidiary, in accordance with applicable laws in Tanzania. The subsidiary was struck off from the Register of Companies in Tanzania with effect from 2 March 2026 pursuant to Section 403(5) of the Tanzania Companies Act, 2002, and has ceased to exist as a legal entity. All assets of the subsidiary were realised and all liabilities and winding-up costs were fully settled.
- 15 Earnings per share for the comparative periods/ year have been retrospectively adjusted for the bonus element in respect of Rights issue.
- 16 The Group has a single operating segment viz. of 'setting up and managing hospitals and medical diagnostic services'

For and on behalf of the Board of Directors



Dr. Manish Mattoo

Bangalore, 19 May 2026

Executive Director, Chief Executive Officer and Chief Financial Officer

